论文部分内容阅读
直接以外消旋乳酸(LA)、L-丙氨酸(Ala)为原料[n(LA)∶n(Ala)=9∶1],采用熔融聚合法合成药物缓释材料聚(乳酸-丙氨酸)共聚物[P(LA-co-Ala)],并用特性黏数、FTIR、1HNMR、GPC、DSC、XRD等手段进行系统表征。熔融共聚中采用一次投料并分次预聚,可生成重均相对分子质量(Mw)达3200(分散度Mw/Mn=1.23)的共聚物,相对分子质量可以达到丙交酯开环共聚法的水平。首次报道了P(LA-co-Ala)]药物缓释材料的DSC与XRD表征结果,其与聚外消旋乳酸(PDLLA)相比,共聚物具有较低的Tg、Tm和结晶度。新方法步骤少、操作简便,且成本更加低廉。
Direct synthesis of drug sustained-release material poly (lactic acid-propylammonium hydroxide) by melt polymerization was carried out by directly using racemic lactate (LA) and L-alanine (Ala) Acid) copolymer [P (LA-co-Ala)] was synthesized and characterized by means of intrinsic viscosity, FTIR, 1HNMR, GPC, DSC and XRD. In the melt copolymerization, one-time charge and pre-polymerization are used to produce a copolymer with a weight average molecular weight (Mw) of 3200 (degree of dispersion Mw / Mn = 1.23), and the relative molecular mass can reach the lactide ring-opening copolymerization Level. The results of DSC and XRD characterization of P (LA-co-Ala) drug sustained-release material were reported for the first time. Compared with PDLLA, the copolymer has lower Tg, Tm and crystallinity. The new method has few steps, is easy to operate, and has lower cost.